Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

Inclusion Criteria: * Healthy self-identified transgender women (male-to-female) between 18-45 years old at the time of screening * Have not undergone an orchiectomy * Receiving oral estradiol and spironolactone for \>/= 3 months prior to study entry with a self-reported adherence to prescribed doses of \>/= 90% * Agree to abstain from alcohol consumption throughout the duration of the study * Be willing to briefly interrupt hormonal therapy prior to and during the study * If on pre-exposure prophylaxis (PrEP) therapy containing tenofovir alafenamide or tenofovir disoproxil fumarate, willing to discontinue PrEP at least 2 weeks before study start and for the duration of the study * Agree to use condoms for all sexual activity prior to the start and throughout the duration of the study * Evidence of a personal signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study Exclusion Criteria: * Presence of clinically significant acute or chronic disease, that in the investigator's opinion, would compromise the participant's safety during the study * Use of injectable or transdermal estradiol * Use of any other hormonal replacement therapy, wit h the exception of oral estradiol and spironolactone * Current use of any antiretroviral drug. This will not be exclusionary if participants reported discontinuing within 30 days of screening * Creatinine clearance \</= 60 mL/min, as estimated by the Cockcroft-Gault eq…